Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Albane Degrassat-Théas"'
Autor:
Karine Szwarcensztein, Hélène Coulonjou, Philippe Lechat, Laurent Mairot, les participants à la table ronde no de Giens Xxxii, Iliona Hounliasso, Nicolas Martelli, Emmanuel Luigi, Albane Degrassat-Théas, Camille Dutot, Cyril Puc, Christophe Roussel, Florence Favrel-Feuillade, Régis Beuscart, Anne-Aurélie Epis de Fleurian, Cécile Vienney, Thao Nguyen, Laurent Piazza
Publikováno v:
Thérapie
Thérapie, EDP Sciences, 2017, 72 (1), pp.105-113. ⟨10.1016/j.therap.2016.11.056⟩
Thérapie, EDP Sciences, 2017, 72 (1), pp.105-113. ⟨10.1016/j.therap.2016.11.056⟩
Resume L’evaluation des technologies de sante (ETS) en milieu hospitalier est une aide a la decision pour l’integration de produits de sante a la structure hospitaliere. Appliquee aux dispositifs medicaux (DM), elle permet d’apprehender plusieu
Autor:
Philippe Lechat, Camille Dutot, Florence Favrel-Feuillade, Laurent Mairot, Christophe Roussel, Emmanuel Luigi, Iliona Hounliasso, Karine Szwarcensztein, Albane Degrassat-Théas, Hélène Coulonjou, Laurent Piazza, Cécile Vienney, Anne-Aurélie Epis de Fleurian, Thao Nguyen, Nicolas Martelli, Régis Beuscart, Cyril Puc
Publikováno v:
Therapies. 72:115-123
Hospital-based health technology assessment (HTA) guides decisions as to whether new healthcare products should be made available within hospital structures. Its extension to medical devices (MDs) makes it possible to analyse several relevant aspects
Autor:
Xiaoyan Lu, Setti Rais Ali, Pascal Paubel, Albane Degrassat-Théas, Laurie Rachet Jacquet, Véronique Raimond, Lise Rochaix
Publikováno v:
Revue française des affaires sociales
Revue française des affaires sociales, La documentation française, 2018, 2018/3, pp.69-89
Revue française des affaires sociales, La documentation française, 2018, 2018/3, pp.69-89
International audience; Early access schemes for pharmaceuticals have been increasingly implemented worldwide with the objective of satisfying unmet medical needs or facilitating market access for certain innovative drugs. It allows for pharmaceutica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58f807ffedcc5541ad45503130b7c93b
https://halshs.archives-ouvertes.fr/halshs-02096440
https://halshs.archives-ouvertes.fr/halshs-02096440
Autor:
Claude Le Pen, Pascal Paubel, Martine Sinègre, Olivier Parent de Curzon, Albane Degrassat-Théas
Publikováno v:
PharmacoEconomics
PharmacoEconomics, 2013, 31 (4), ⟨10.1007/s40273-013-0039-4⟩
PharmacoEconomics, 2013, 31 (4), 〈10.1007/s40273-013-0039-4〉
PharmacoEconomics, 2013, 31 (4), ⟨10.1007/s40273-013-0039-4⟩
PharmacoEconomics, 2013, 31 (4), 〈10.1007/s40273-013-0039-4〉
International audience; BackgroundTo reach the French market, a new drug requires a marketing authorization (MA) and price and reimbursement agreements. These hurdles could delay access to new and promising drugs. Since 1992, French law authorizes th
Publikováno v:
PharmacoEconomics
PharmacoEconomics, 2012, 30 (7), 〈10.2165/11588320-000000000-00000〉
PharmacoEconomics, 2012, 30 (7), ⟨10.2165/11588320-000000000-00000⟩
PharmacoEconomics, 2012, 30 (7), 〈10.2165/11588320-000000000-00000〉
PharmacoEconomics, 2012, 30 (7), ⟨10.2165/11588320-000000000-00000⟩
Background:Background: In 2005, the French Government implemented a new way of financing high-cost drugs for hospitals in order to promote innovation. Such drugs are gathered on a positive list, established by the Ministry of Health, with a reimburse